Key result
The Terumo Aortic TREO abdominal aortic stent-graft demonstrated excellent performance in clinical outcomes for endovascular aneurysm repair based on a review of US and global experience.
Why the study?
Long-term endovascular aneurysm repair is hindered by the need for reintervention, prompting device improvements directed toward improving long-term outcomes.
The Terumo Aortic TREO abdominal aortic stent-graft, approved by the FDA in 2020, demonstrates excellent clinical performance for endovascular aneurysm repair.
Supports TREO consideration in EVAR; extends observational data but leaves open need for randomized trials.
Endovascular aneurysm repair has become a primary treatment modality for patients with abdominal aortic aneurysms due to its less invasive nature and improved peri-operative mortality rates compared with conventional open surgery. Long-term, endovascular aneurysm repair is hindered by the need for reintervention due to a variety of reasons. Device improvements are directed toward improving these long-term outcomes. The current manuscript highlights some of the details of the Terumo Aortic TREO abdominal aortic stent-graft, which was approved in 2020 for clinical use by the US FDA. A brief review of the available clinical outcomes from the US trial, as well as experience in the rest of the world, are provided demonstrating its excellent performance.
No takes yet. Share an insight, caveat, or question.
Boitano et al. (2020) conducted a review in Abdominal aortic aneurysms. Terumo Aortic TREO abdominal aortic stent-graft was evaluated. The Terumo Aortic TREO abdominal aortic stent-graft demonstrated excellent performance in clinical outcomes for endovascular aneurysm repair based on a review of US and global experience.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: